Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 2Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Rituximab 4Tacrolimus 3fludarabine 2cobomarsen 2Peripheral Blood Stem Cell Transplantation 2Ganciclovir 2Etoposide 2Cyclophosphamide 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine phosphate 1ferric carboxymaltose 1epratuzumab 1denileukin diftitox 1dacetuzumab 1beta-Glucans 1arginine butyrate 1Vorinostat 1Vincristine 1Valganciclovir 1Stem Cell Transplantation 1Sirolimus 1Prednisone 1Oxycodone 1Mycophenolic Acid 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoproliferative Disorders × denileukin diftitox × Clear all
NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡